通过控制血压维持糖尿病肾病患者的肾功能

H. Bando, Noboru Iwatsuki, M. Okada, T. Ogawa, K. Sakamoto
{"title":"通过控制血压维持糖尿病肾病患者的肾功能","authors":"H. Bando, Noboru Iwatsuki, M. Okada, T. Ogawa, K. Sakamoto","doi":"10.36502/2023/asjbccr.6305","DOIUrl":null,"url":null,"abstract":"The case involves a 74-year-old male with type 2 diabetes (T2D), hypertension, dyslipidemia, and diabetic kidney disease (DKD) at nephropathy stage G3b. He has been receiving treatment with insulin and anti-hypertensive agents (AHAs). In July 2021, his HbA1c was elevated to 7.9%. As a result, the extent of his low carbohydrate diet (LCD) was increased, and insulin doses were raised. The AHAs were changed from Olmesartan to Valsartan/Amlodipine, and Irbesartan/Amlodipine until 2023. By January 2023, his HbA1c had decreased to 6.8%, and his eGFR (CKD-EPI) had remained stable at 34-48 mL/min/1.73/m2 for 4 years. A recent study demonstrated clinical improvement in renal function through continuous LCD in patients with DKD.","PeriodicalId":93523,"journal":{"name":"Asploro journal of biomedical and clinical case reports","volume":" ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2023-06-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Maintained Renal Function by Blood Pressure Control in Patient with Diabetic Kidney Disease (DKD)\",\"authors\":\"H. Bando, Noboru Iwatsuki, M. Okada, T. Ogawa, K. Sakamoto\",\"doi\":\"10.36502/2023/asjbccr.6305\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"The case involves a 74-year-old male with type 2 diabetes (T2D), hypertension, dyslipidemia, and diabetic kidney disease (DKD) at nephropathy stage G3b. He has been receiving treatment with insulin and anti-hypertensive agents (AHAs). In July 2021, his HbA1c was elevated to 7.9%. As a result, the extent of his low carbohydrate diet (LCD) was increased, and insulin doses were raised. The AHAs were changed from Olmesartan to Valsartan/Amlodipine, and Irbesartan/Amlodipine until 2023. By January 2023, his HbA1c had decreased to 6.8%, and his eGFR (CKD-EPI) had remained stable at 34-48 mL/min/1.73/m2 for 4 years. A recent study demonstrated clinical improvement in renal function through continuous LCD in patients with DKD.\",\"PeriodicalId\":93523,\"journal\":{\"name\":\"Asploro journal of biomedical and clinical case reports\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-06-24\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Asploro journal of biomedical and clinical case reports\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.36502/2023/asjbccr.6305\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Asploro journal of biomedical and clinical case reports","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.36502/2023/asjbccr.6305","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

该病例涉及一名74岁男性,患有2型糖尿病(T2D)、高血压、血脂异常和肾病G3b期糖尿病肾病(DKD)。他一直在接受胰岛素和抗高血压药物(AHA)的治疗。2021年7月,他的HbA1c升高至7.9%。因此,他的低碳水化合物饮食(LCD)范围增加,胰岛素剂量增加。AHA从奥美沙坦改为缬沙坦/氨氯地平,并在2023年前改为厄贝沙坦/氨氯地平。到2023年1月,他的HbA1c已降至6.8%,他的eGFR(CKD-EPI)在4年内稳定在34-48 mL/min/1.73/m2。最近的一项研究表明,DKD患者通过连续液晶显示可改善肾功能。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Maintained Renal Function by Blood Pressure Control in Patient with Diabetic Kidney Disease (DKD)
The case involves a 74-year-old male with type 2 diabetes (T2D), hypertension, dyslipidemia, and diabetic kidney disease (DKD) at nephropathy stage G3b. He has been receiving treatment with insulin and anti-hypertensive agents (AHAs). In July 2021, his HbA1c was elevated to 7.9%. As a result, the extent of his low carbohydrate diet (LCD) was increased, and insulin doses were raised. The AHAs were changed from Olmesartan to Valsartan/Amlodipine, and Irbesartan/Amlodipine until 2023. By January 2023, his HbA1c had decreased to 6.8%, and his eGFR (CKD-EPI) had remained stable at 34-48 mL/min/1.73/m2 for 4 years. A recent study demonstrated clinical improvement in renal function through continuous LCD in patients with DKD.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信